肥満細胞症治療薬の世界市場レポート2025年

肥満細胞症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.5％で16億8,000万米ドルに成長します。予測期間中に予測される成長は、希少疾患治療への重点化、個別化医療の台頭、アレルギーや免疫系疾患の罹患率の増加、支持療法の利用拡大、開発中の医薬品パイプラインの拡大に起因しています。この期間に予想される主要動向としては、医療研究の進展、標的治療法の開発、遺伝子研究の発展、併用療法アプローチの採用、ドラッグデリバリー技術の革新などが挙げられます。

希少疾患への投資の増加は、今後数年間の肥満細胞症治療薬市場の成長を牽引すると予想されます。希少疾患とは、人口のごく一部が罹患する疾患であり、米国では通常20万人以下、欧州のでは2,000人に1人以下です。このセグメントへの投資が増加しているのは、希少疾病用医薬品の指定、市場独占権の延長、税額控除といった規制上の優遇措置が充実してきたことが大きな要因であり、これらの優遇措置は開発リスクを低減し、製薬企業の収益性を向上させるのに役立っています。肥満細胞症治療薬は、肥満細胞症の症状管理に役立つだけでなく、同様の免疫経路や細胞経路を共有する他の希少疾患の治療法の進歩にも貢献する標的治療を記載しています。例えば、2024年4月、米国の非営利団体Global Genesは、2024年第1四半期に希少疾患治療開発に注力する会社が公開株式と債券による資金調達を通じて71億米ドルを調達したと報告しました。その結果、希少疾患への投資の増加が肥満細胞症治療薬市場の拡大に拍車をかけています。

肥満細胞症治療薬市場の主要企業は、チロシンキナーゼ阻害剤などの革新的な治療法の開拓に注力し、治療効果を高め、進行性肥満細胞症患者に的を絞ったソリューションを提供しています。チロシンキナーゼ阻害剤は、細胞の異常増殖に関与する酵素を阻害する薬剤です。肥満細胞症の場合、これらの薬剤は肥満細胞の過剰な増殖を阻害することで作用し、それによって発疹や炎症などの症状を軽減します。例えば、2023年5月、米国のバイオテクノロジー企業であるBlueprint Medicines Corporationは、成人の低悪性度全身性肥満細胞症（ISM）の治療として、Ayvakit（アバプリチニブ）の承認を米国食品医薬品局から取得しました。この承認は、肥満細胞の過剰産生を特徴とするまれで慢性的な疾患であるISMの管理における重要な前進を意味します。Ayvakitは、ISM患者によく見られるKIT D816V変異を標的とする選択的阻害剤であり、症状コントロールと疾患管理のための集中的な治療選択肢を記載しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肥満細胞症治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の肥満細胞症治療薬市場：成長率分析
• 世界の肥満細胞症治療薬市場の実績：規模と成長、2019～2024年
• 世界の肥満細胞症治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の肥満細胞症治療薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の肥満細胞症治療薬市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗ヒスタミン薬
• コルチコステロイド
• 肥満細胞安定剤
• 世界の肥満細胞症治療薬市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 全身性肥満細胞症
• 皮膚肥満細胞症
• 肥満細胞活性化症候群
• 世界の肥満細胞症治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• 皮下
• 世界の肥満細胞症治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売業者
• その他
• 世界の肥満細胞症治療薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 在宅医療
• 専門クリニック
• その他
• 世界の肥満細胞症治療薬市場、抗ヒスタミン薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• H1受容体拮抗薬
• H2受容体拮抗薬
• 世界の肥満細胞症治療薬市場、コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 局所コルチコステロイド
• 経口コルチコステロイド
• 静脈内コルチコステロイド
• 世界の肥満細胞症治療薬市場、肥満細胞安定剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• クロモグリク酸ナトリウム
• ケトチフェン
• ネドクロミル

第7章 地域別・国別分析

• 世界の肥満細胞症治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の肥満細胞症治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肥満細胞症治療薬市場：競合情勢
• 肥満細胞症治療薬市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer AG
  • Sanofi S.A.
  • Novartis AG

第31章 その他の大手企業と革新的企業

• GSK plc
• Teva Pharmaceutical Industries Limited
• Alcon Inc.
• Bausch Health Companies Inc.
• Genentech Inc.
• Lupin Limited
• Blueprint Medicines Corporation
• Don Valley Pharma（Pvt.）Ltd.
• Vivan Life Sciences Private Limited
• AB Science S.A.
• Medoz Pharmaceutical Private Limited
• Zumax Biocare Private Limited
• Hi-Cure BIoTech Private Limited
• Zenomed Healthcare Private Limited
• Biosynth AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 肥満細胞症治療薬市場、2029年：新たな機会を提供する国
• 肥満細胞症治療薬市場、2029年：新たな機会を提供するセグメント
• 肥満細胞症治療薬市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Mastocytosis drugs are medications used to treat mastocytosis, a rare disorder marked by the abnormal buildup of mast cells in the skin, bone marrow, and internal organs. These medications are designed to manage symptoms, suppress mast cell activity, or address more aggressive forms of the condition.

The primary types of mastocytosis drugs include antihistamines, corticosteroids, and mast cell stabilizers. Antihistamines serve as first-line treatments by alleviating symptoms through the prevention of histamine from binding to its receptors during allergic responses. These drugs are used to manage conditions such as systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome. They can be administered orally, intravenously, or subcutaneously. Distribution occurs through hospital pharmacies, online pharmacies, retail stores, and other channels. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The mastocytosis drug market research report is one of a series of new reports from The Business Research Company that provides mastocytosis drug market statistics, including the mastocytosis drug industry global market size, regional shares, competitors with the mastocytosis drug market share, detailed mastocytosis drug market segments, market trends, and opportunities, and any further data you may need to thrive in the mastocytosis drug industry. This mastocytosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mastocytosis drug market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period can be attributed to an aging population, a rising prevalence of blood cancers, increased utilization of biologic and immunotherapies, growing healthcare spending, and a higher incidence of mastocytosis.

The mastocytosis drug market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The projected growth during the forecast period can be attributed to a growing emphasis on rare disease treatments, the emergence of personalized medicine, an increasing incidence of allergies and immune system disorders, greater use of supportive therapies, and an expanding pipeline of drugs in development. Key trends anticipated during this period include progress in medical research, the development of targeted treatment options, advancements in genetic research, the adoption of combination therapy approaches, and innovations in drug delivery technologies.

The rising investment in rare diseases is expected to drive the growth of the mastocytosis drug market in the coming years. Rare diseases are medical conditions that impact a small portion of the population-typically fewer than 200,000 individuals in the United States or fewer than 1 in 2,000 people in Europe. Increased investment in this area is largely fueled by growing regulatory incentives such as orphan drug designations, extended market exclusivity, and tax credits, which help lower development risks and improve profitability for pharmaceutical companies. Mastocytosis drugs provide targeted treatment that not only helps manage mastocytosis symptoms but also contributes to the advancement of therapies for other rare diseases sharing similar immune or cellular pathways. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that in the first quarter of 2024, companies focused on rare disease drug development raised $7.1 billion through public equity and debt financings-a 307% increase compared to the $1.8 billion raised during the same period in 2023. As a result, rising investment in rare diseases is fueling the expansion of the mastocytosis drug market.

Leading companies in the mastocytosis drug market are concentrating on developing innovative treatments such as tyrosine kinase inhibitors to enhance therapeutic effectiveness and offer targeted solutions for patients with advanced mast cell disorders. Tyrosine kinase inhibitors are medications that block enzymes involved in abnormal cell growth. In the context of mastocytosis, these drugs work by inhibiting the excessive growth of mast cells, thereby reducing symptoms like rashes and inflammation. For example, in May 2023, Blueprint Medicines Corporation, a biotechnology company based in the U.S., received approval from the U.S. Food and Drug Administration for Ayvakit (avapritinib) to treat adults with indolent systemic mastocytosis (ISM). This approval represents a significant step forward in managing ISM, a rare and chronic condition marked by the overproduction of mast cells. Ayvakit is a selective inhibitor targeting the KIT D816V mutation, which is commonly found in ISM patients, providing a focused treatment option for symptom control and disease management.

In May 2024, Incyte Corporation, a biopharmaceutical company based in the United States, acquired Escient Pharmaceuticals for approximately $750 million. This acquisition is intended to bolster Incyte's Inflammation and Autoimmunity (IAI) pipeline by incorporating Escient Pharmaceuticals' first-in-class oral MRGPR antagonists, thereby enhancing its ability to develop novel therapies for serious immune and neuro-immune conditions. Escient Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing EP262, a first-in-class oral MRGPRX2 antagonist aimed at treating mast cell-mediated diseases.

Major players in the mastocytosis drug market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK plc, Teva Pharmaceutical Industries Limited, Alcon Inc., Bausch Health Companies Inc., Genentech Inc., Lupin Limited, Blueprint Medicines Corporation, Don Valley Pharma (Pvt.) Ltd., Vivan Life Sciences Private Limited, AB Science S.A., Medoz Pharmaceutical Private Limited, Zumax Biocare Private Limited, Hi-Cure Biotech Private Limited, Zenomed Healthcare Private Limited, Biosynth AG.

North America was the largest region in the mastocytosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mastocytosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mastocytosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mastocytosis drug market also includes sales of antihistamines, leukotriene receptor antagonists, corticosteroids, tyrosine kinase inhibitors (TKIs), and epinephrine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mastocytosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mastocytosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mastocytosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mastocytosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Antihistamines; Corticosteroids; Mast Cell Stabilizers
• 2) By Disease Type: Systemic Mastocytosis; Cutaneous Mastocytosis; Mast Cell Activation Syndrome
• 3) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retailers; Other Distribution Channels
• 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Antihistamines: H1-Receptor Antagonists; H2-Receptor Antagonists
• 2) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Intravenous Corticosteroids
• 3) By Mast Cell Stabilizers: Cromolyn sodium; Ketotifen; Nedocromil
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Bayer AG; Sanofi S.A.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mastocytosis Drug Market Characteristics

3. Mastocytosis Drug Market Trends And Strategies

4. Mastocytosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Mastocytosis Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Mastocytosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Mastocytosis Drug Market Growth Rate Analysis
• 5.4. Global Mastocytosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Mastocytosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Mastocytosis Drug Total Addressable Market (TAM)

6. Mastocytosis Drug Market Segmentation

• 6.1. Global Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamines
• Corticosteroids
• Mast Cell Stabilizers
• 6.2. Global Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Mastocytosis
• Cutaneous Mastocytosis
• Mast Cell Activation Syndrome
• 6.3. Global Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.4. Global Mastocytosis Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retailers
• Other Distribution Channels
• 6.5. Global Mastocytosis Drug Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Mastocytosis Drug Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• H1-Receptor Antagonists
• H2-Receptor Antagonists
• 6.7. Global Mastocytosis Drug Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids
• Oral Corticosteroids
• Intravenous Corticosteroids
• 6.8. Global Mastocytosis Drug Market, Sub-Segmentation Of Mast Cell Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cromolyn sodium
• Ketotifen
• Nedocromil

7. Mastocytosis Drug Market Regional And Country Analysis

• 7.1. Global Mastocytosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Mastocytosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Mastocytosis Drug Market

• 8.1. Asia-Pacific Mastocytosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Mastocytosis Drug Market

• 9.1. China Mastocytosis Drug Market Overview
• 9.2. China Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Mastocytosis Drug Market

• 10.1. India Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Mastocytosis Drug Market

• 11.1. Japan Mastocytosis Drug Market Overview
• 11.2. Japan Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Mastocytosis Drug Market

• 12.1. Australia Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Mastocytosis Drug Market

• 13.1. Indonesia Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Mastocytosis Drug Market

• 14.1. South Korea Mastocytosis Drug Market Overview
• 14.2. South Korea Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Mastocytosis Drug Market

• 15.1. Western Europe Mastocytosis Drug Market Overview
• 15.2. Western Europe Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Mastocytosis Drug Market

• 16.1. UK Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Mastocytosis Drug Market

• 17.1. Germany Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Mastocytosis Drug Market

• 18.1. France Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Mastocytosis Drug Market

• 19.1. Italy Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Mastocytosis Drug Market

• 20.1. Spain Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Mastocytosis Drug Market

• 21.1. Eastern Europe Mastocytosis Drug Market Overview
• 21.2. Eastern Europe Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Mastocytosis Drug Market

• 22.1. Russia Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Mastocytosis Drug Market

• 23.1. North America Mastocytosis Drug Market Overview
• 23.2. North America Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Mastocytosis Drug Market

• 24.1. USA Mastocytosis Drug Market Overview
• 24.2. USA Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Mastocytosis Drug Market

• 25.1. Canada Mastocytosis Drug Market Overview
• 25.2. Canada Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Mastocytosis Drug Market

• 26.1. South America Mastocytosis Drug Market Overview
• 26.2. South America Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Mastocytosis Drug Market

• 27.1. Brazil Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Mastocytosis Drug Market

• 28.1. Middle East Mastocytosis Drug Market Overview
• 28.2. Middle East Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Mastocytosis Drug Market

• 29.1. Africa Mastocytosis Drug Market Overview
• 29.2. Africa Mastocytosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Mastocytosis Drug Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Mastocytosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Mastocytosis Drug Market Competitive Landscape And Company Profiles

• 30.1. Mastocytosis Drug Market Competitive Landscape
• 30.2. Mastocytosis Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Mastocytosis Drug Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Teva Pharmaceutical Industries Limited
• 31.3. Alcon Inc.
• 31.4. Bausch Health Companies Inc.
• 31.5. Genentech Inc.
• 31.6. Lupin Limited
• 31.7. Blueprint Medicines Corporation
• 31.8. Don Valley Pharma (Pvt.) Ltd.
• 31.9. Vivan Life Sciences Private Limited
• 31.10. AB Science S.A.
• 31.11. Medoz Pharmaceutical Private Limited
• 31.12. Zumax Biocare Private Limited
• 31.13. Hi-Cure Biotech Private Limited
• 31.14. Zenomed Healthcare Private Limited
• 31.15. Biosynth AG

32. Global Mastocytosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mastocytosis Drug Market

34. Recent Developments In The Mastocytosis Drug Market

35. Mastocytosis Drug Market High Potential Countries, Segments and Strategies

• 35.1 Mastocytosis Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Mastocytosis Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Mastocytosis Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer